P-52 Prevalence and outcomes of triple negative breast cancer in female patients at the Oncology Department, Georgetown Public Hospital Corporation, January 2019 to January 2024
Author(s):
C Frank, L Gooding, D Boodhoo, D Carter, F Langevine
Year of Presentation:
2026
Objective: To identify the prevalence and outcomes of
triple-negative breast cancer (TNBC) in female patients at
the Oncology Department of Georgetown Public Hospital
Corporation (GPHC).
Methods: A representative sample of 200 charts of patients with breast cancer was selected by random sampling, and the data was stratified based on ethnicity, age, general location, stage, treatment received and outcome. The results were critically analyzed in comparison to global standards of treatment of TNBC.
Results: Of the 200 charts reviewed, 30 patients (15%) had TNBC. Among TNBC patients the largest age and ethnic groups were >64 years (39%) and Afro-Guyanese (50%) respectively. At diagnosis, 10% were Stage I, 36.7% Stage II, 26.7% Stage III, 6.7% Stage IV, and 20% undocumented. Treatments included surgery followed by chemotherapy (31%), surgery only (24.1%), surgery with chemotherapy followed by external beam radiation therapy (EBRT) (17.2%), chemotherapy only (13.8%), and undocumented modalities (13.8%). Surgery was performed first in multimodal therapy. Outcomes: 2 remissions, 2 recurrences, 6 ongoing treatment, 10 follow-up, and 10 undocumented.
Conclusion: At GPHC, although triple-negative breast cancer prevalence was relatively low, and current treatment yields generally positive outcomes, earlier detection, routine neoadjuvant chemotherapy, and improved EBRT access are needed to optimize care.